Inulin: properties, uses, pros, cons, safety
Inulin is a soluble dietary fiber extracted from the root of Cichorium intybus and from other plants Chemically, it is a fructan, meaning a chain of fructose molecules ending with one glucose molecule. The length of the chain (degree of polymerization) influences its properties.
Definition
Inulin is a natural polysaccharide, indigestible by the human small intestine. It reaches the colon, where it acts as a prebiotic: it nourishes gut bacteria (particularly bifidobacteria), supporting the microbiota’s health.
Production process
Chicory inulin is industrially extracted from the roots. The process involves water extraction, purification, and concentration. Depending on processing, inulins of different chain lengths (short-chain or long-chain) are obtained.
Main constituents
Being a fiber, it consists mainly of fructose chains, with one terminal glucose molecule. It contains no significant other substances in purified form.
Identification data and specifications
| Characteristic | Value | Note |
|---|
| Name | chicory inulin | prebiotic fiber |
| Molecular formula | variable (C₆H₁₀O₅)ₙ | polysaccharide (fructan) |
| CAS number | 9005-80-5 | substance identifier |
| Caloric value | approx. 1.5 kcal/g | colonic fermentation |
| Food function | soluble fiber, prebiotic | microbiota support |
Physicochemical properties (indicative)
| Characteristic | Indicative value | Note |
|---|
| Physical state | powder/small granules | from white to light beige |
| Water solubility | good | forms viscous solutions |
| Taste | mildly sweet | sweetness about 10% of sucrose |
| Heat stability | good | stable in cooking processes |
| Effect on pH | neutral | does not alter pH |
| Intestinal fermentation | high | promotes beneficial flora |
Functional role and mechanism of action
Inulin is not digested in the stomach or small intestine. It reaches the colon, where gut bacteria ferment it, producing short-chain fatty acids (SCFAs) that have beneficial effects on gut health. It supports the growth of “good” bacteria (e.g., bifidobacteria), contributing to microbiota well-being. In some food formulations, it is used to enhance texture or partially replace sugars or fats.
Main uses in food
Prebiotic: supports gut health and the balance of gut flora.
Texture enhancement: used to add body to low-fat products.
Sugar replacement: to reduce calories and increase fiber in functional or diet foods.
Fiber fortification: added to baked goods, dairy products, bars, and beverages.
Pros and cons
Pros
Prebiotic: supports the intestinal microbiota.
Versatility: used in a wide range of food formulations (from dairy to baked goods).
Low glycemic impact: does not cause glucose spikes (useful for low glycemic index products).
Improves texture: can add creaminess or body to products with reduced fat content.
Cons
Fermentation: at high doses, it can cause bloating, gas, and intestinal discomfort.
Individual tolerance: some sensitive individuals may experience gastrointestinal distress.
Limited solubility at high concentrations: in certain formulations, if unbalanced, it may result in undesirable texture.
Safety, regulatory, and practical aspects
Safety profile in the finished product
Inulin is considered safe as a food ingredient. It is approved in the EU and many other countries for use in foods. There is no strict dosage limit, but a gradual introduction into the diet is recommended to avoid gastrointestinal effects.
Allergen
It is not an allergen. However, individuals with irritable bowel syndrome (IBS) or sensitivity to FODMAPs (fermentable carbohydrates) may need to limit intake.
Practical guidance
It is advised to test individual tolerance and increase inulin intake gradually. In supplementation, inulin is often dosed between 5 and 10 g per day, though in functional foods the quantity may vary according to the recipe.
Conclusion
Inulin is a versatile prebiotic fiber, with uses ranging from promoting gut microbiota to modulating food texture. Its key benefits lie in its prebiotic function and its use as a functional ingredient. The main limitation is individual intestinal tolerance, which requires attention to dosage.
Studies
Improves and cures digestive functions (1) reducing the risk of colon cancer (2).
Improves and reduces the values of harmful cholesterol (3).
Not being assimilated by the body, it does not affect glucose levels, but modulates them (4). It is therefore a food suitable for diabetics.
The most relevant studies on this carbohydrate have been selected with a summary of their contents:
Inulin studies
References______________________________________________________________________
(1) Gibson GR, Beatty ER, Wang X, Cummings JH Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995 Apr; 108(4):975-82.
Abstract. Background/aims: Oligofructose and inulin are naturally occurring indigestible carbohydrates. In vitro they selectively stimulate the growth of species of Bifidobacterium, a genus of bacteria considered beneficial to health. This study was designed to determine their effects on the large bowel microflora and colonic function in vivo. Methods: Eight subjects participated in a 45-day study during which they ate controlled diets. For the middle 15 days, 15 g.day-1 oligofructose was substituted for 15 g.day-1 sucrose. Four of these subjects went on to a further period with 15 g.day-1 inulin. Bowel habit, transit time, stool composition, breath H2 and CH4, and the predominant genera of colonic bacteria were measured. Results: Both oligofructose and inulin significantly increased bifidobacteria from 8.8 to 9.5 log10 g stool-1 and 9.2 to 10.1 log10 g stool-1, respectively, whereas bacteroides, clostridia, and fusobacteria decreased when subjects were fed oligofructose, and gram-positive cocci decreased when subjects were fed inulin. Total bacterial counts were unchanged. Fecal wet and dry matter, nitrogen, and energy excretion increased with both substrates, as did breath H2. Little change in fecal short-chain fatty acids and breath CH4 was observed. Conclusions: A 15-g.day-1 dietary addition of oligofructose or inulin led to Bifidobacterium becoming the numerically predominant genus in feces. Thus, small changes in diet can alter the balance of colonic bacteria towards a potentially healthier microflora.
(2) Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, Klinder A, O'Riordan M, O'Sullivan GC, Pool-Zobel B, Rechkemmer G, Roller M, Rowland I, Salvadori M, Thijs H, Van Loo J, Watzl B, Collins JK Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr. 2007 Feb; 85(2):488-96.
Abstract. Background: Animal studies suggest that prebiotics and probiotics exert protective effects against tumor development in the colon, but human data supporting this suggestion are weak. Objective: The objective was to verify whether the prebiotic concept (selective interaction with colonic flora of nondigested carbohydrates) as induced by a synbiotic preparation-oligofructose-enriched inulin (SYN1) + Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis Bb12 (BB12)-is able to reduce the risk of colon cancer in humans. Design: The 12-wk randomized, double-blind, placebo-controlled trial of a synbiotic food composed of the prebiotic SYN1 and probiotics LGG and BB12 was conducted in 37 colon cancer patients and 43 polypectomized patients. Fecal and blood samples were obtained before, during, and after the intervention, and colorectal biopsy samples were obtained before and after the intervention. The effect of synbiotic consumption on a battery of intermediate bio-markers for colon cancer was examined. Results: Synbiotic intervention resulted in significant changes in fecal flora: Bifidobacterium and Lactobacillus increased and Clostridium perfringens decreased. The intervention significantly reduced colorectal proliferation and the capacity of fecal water to induce necrosis in colonic cells and improve epithelial barrier function in polypectomized patients. Genotoxicity assays of colonic biopsy samples indicated a decreased exposure to genotoxins in polypectomized patients at the end of the intervention period. Synbiotic consumption prevented an increased secretion of interleukin 2 by peripheral blood mononuclear cells in the polypectomized patients and increased the production of interferon gamma in the cancer patients.
(3) de Luis DA, de la Fuente B, Izaola O, Conde R, Gutiérrez S, Morillo M, Teba Torres C. Randomized clinical trial with a inulin enriched cookie on risk cardiovascular factor in obese patients. Nutr Hosp. 2010 Jan-Feb;25(1):53-9.
Abstract. Introduction: Inulin is a prebiotic with potential benefit in cardiovascular risk factors. The aim of our work is to evaluate in obese patients the effect of a inulin enriched cookie on cardiovascular risk factors. Material and methods: 34 patients were randomized in both branches: group I (inulin enriched cookie) Gullon SL(R) and group II (control cookie). Previous and after 1 month of the treatment, a nutritional and biochemical study was realized. Results: 15 patients finished the procotol in each group. In group I, an increase in soluble fiber intake (inulin) was detected. In this group a significant decrease of total cholesterol (223.1 +/- 45.3 mg/dl vs 208.8 +/- 33.1 mg/dl; p < 0.05) and LDL cholesterol (142.9 +/- 39.2 mg/dl vs 131.4 +/- 28.6 mg/dl; p < 0.05) was reached. A non significant improvement in insulin levels and HOMA was detected in inulin-enriched cookie group, too. Anthropometric parameters did not change in both groups. The increase in soluble fiber intake did not produce any gastrointestinal adverse effect. Conclusion: The increase of fiber intake (3 g of inulin) from an enriched cookie reduced LDL cholesterol levels in obese patients.
(4) Verbrugghe A, Hesta M, Gommeren K, Daminet S, Wuyts B, Buyse J, Janssens GP. Oligofructose and inulin modulate glucose and amino acid metabolism through propionate production in normal-weight and obese cats. Br J Nutr. 2009 Sep;102(5):694-702. doi: 10.1017/S0007114509288982.
Abstract. The effect of dietary oligofructose and inulin supplementation on glucose metabolism in obese and non-obese cats was assessed. Two diets were tested in a crossover design; a control diet high in protein (46 % on DM basis), moderate in fat (15 %), low in carbohydrates (27 %), but no soluble fibres added; and a prebiotic diet, with 2.5 % of a mixture of oligofructose and inulin added to the control diet. Eight non-obese and eight obese cats were allotted to each of two diets in random order at intervals of 4 weeks. At the end of each testing period, intravenous glucose tolerance tests were performed. Area under the glucose curve (AUCgluc) was increased (P = 0.022) and the second insulin peak was delayed (P = 0.009) in obese compared to non-obese cats. Diets did not affect fasting plasma glucose concentrations, blood glucose response at each glucose time-point after glucose administration, AUCgluc, fasting serum insulin concentrations, area under the insulin curve, and height and appearance time of insulin response. Yet, analysis of acylcarnitines revealed higher propionylcarnitine concentrations (P = 0.03) when fed the prebiotic diet, suggesting colonic fermentation and propionate absorption. Prebiotic supplementation reduced methylmalonylcarnitine (P = 0.072) and aspartate aminotransferase concentrations (P = 0.025), both indicating reduced gluconeogenesis from amino acids. This trial evidenced impaired glucose tolerance and altered insulin response to glucose administration in obese compared to non-obese cats, regardless of dietary intervention; yet modulation of glucose metabolism by enhancing gluconeogenesis from propionate and inhibition of amino acid catabolism can be suggested.
Inulin 
